a Department of Hematology , ICO-Hospital Germans Trias i Pujol. Institut de Recerca Josep Carreras, Universitat Autònoma de Barcelona , Badalona , Spain.
Leuk Lymphoma. 2018 Nov;59(11):2602-2611. doi: 10.1080/10428194.2018.1448085. Epub 2018 Mar 21.
Lenalidomide has been associated with an increased risk of venous thromboembolism (VTE) in multiple myeloma. It is unclear whether patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) are also at such risk. We conducted a systematic review of the incidence of VTE in prospective trials of lenalidomide-treated patients with NHL or CLL. Sixty-eight unique reports were assessed for inclusion. For grade ≥3 VTE, 98 events were reported in 3043 patients (60 studies) (crude incidence: 3.22% [95% confidence interval: 2.6-3.9%]). For any grade VTE, 97 events were reported in 2244 patients (46 studies) (crude incidence: 4.32% [3.5-5.2%]). Subgroup analysis showed no difference based on histological subtype or use of prophylaxis. The study is at risk of bias, largely due to insufficient data from the individual studies. Within the limitations of this systematic review, we found a low risk of VTE in patients with NHL treated with lenalidomide.
来那度胺与多发性骨髓瘤患者的静脉血栓栓塞（VTE）风险增加有关。目前尚不清楚非霍奇金淋巴瘤（NHL）和慢性淋巴细胞白血病（CLL）患者是否也存在这种风险。我们对接受来那度胺治疗的 NHL 或 CLL 患者的前瞻性试验中 VTE 的发生率进行了系统评价。评估了 68 份独特的报告以纳入研究。对于≥3 级 VTE，在 3043 名患者（60 项研究）中报告了 98 例事件（粗发生率：3.22%[95%置信区间：2.6-3.9%]）。对于任何级别 VTE，在 2244 名患者（46 项研究）中报告了 97 例事件（粗发生率：4.32%[3.5-5.2%]）。亚组分析表明，组织学亚型或预防治疗的使用并无差异。该研究存在偏倚风险，主要是由于个别研究的数据不足。在本系统评价的局限性内，我们发现 NHL 患者接受来那度胺治疗时 VTE 的风险较低。
